Amgen Inc. is pinning its hopes on a groundbreaking obesity drug called MariTide, developed using DNA samples from nearly 200,000 Icelanders. The samples, stored in a freezer at the University of Iceland Science Park in Reykjavík, were crucial in engineering the weight-loss injection, which is now the center of attention in Amgen’s pipeline.
The drug’s development marks a pivotal moment for Amgen, as it aims to break into a highly competitive obesity drug market projected to exceed $120 billion in annual sales. With rivals Eli Lilly & Co. and Novo Nordisk A/S already leading the space, MariTide faces high expectations as it nears its development timeline.
Investor interest in MariTide has been intense, given the potential for it to become one of Amgen’s most significant products. The company will likely face questions about the drug’s prospects when it reports earnings on Tuesday, as analysts and investors assess whether MariTide can stand out in a crowded market.
The success of MariTide will also test Amgen’s genetics-driven research strategy, which the company has been refining for over a decade. The outcome could shape the future of obesity treatments and solidify Amgen’s position in the pharmaceutical industry.